Orion (OEC)

NYSE Mercado fechado

Orion S.A. is a global producer of carbon black, a finely divided form of carbon used to change the strength, durability, conductivity, colour, and processing characteristics of industrial materials. The company supplies customers across automotive, tire, coatings, plastics, printing, battery, and other specialty markets, making it part of the chemical supply chain behind many everyday and industrial products.

Orion reports its business through two main segments: Rubber Carbon Black and Specialty Carbon Black. Rubber Carbon Black is the larger revenue contributor and is primarily used to reinforce tires and mechanical rubber goods, where it helps improve wear resistance, tensile strength, and overall performance. Demand in this segment is closely tied to tire production, vehicle use, replacement tire cycles, and broader industrial activity.

The Specialty Carbon Black segment serves higher-value applications where carbon black functions as a pigment or performance additive. These products are used in coatings, inks, polymers, cables, conductive compounds, and other applications that require specific colour, electrical, or technical properties. Specialty grades can be more customized than standard rubber grades, giving Orion exposure to markets where material performance is a key purchasing factor.

The company operates internationally, with a significant revenue base in Europe and particularly Germany, according to its reported geographic mix. Orion’s position is shaped by manufacturing scale, technical know-how, customer qualification requirements, and the need to meet environmental and quality standards in a heavily regulated chemicals industry.

6.72 USD
6.00 USD
−0.46 (-6.41%)
Pós-mercado

Última atualização

Valor de mercado
404.87M
P/L
Preço/FCF
11.53
P/Receita
0.23
Valor da empresa
1.37B
Setor
Indústria
Endereço
1700 CITY PLAZA DRIVE, SUITE 300, SPRING, TX, 77389
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2026

23 de abr. de 2026, 06:00 AM
GlobeNewswire Inc.

Gabelli Hosts 17th Annual Specialty Chemicals Symposium

24 de fev. de 2026, 10:00 AM
GlobeNewswire Inc.

Orion Group Interim Report January–September 2025

28 de out. de 2025, 07:00 AM
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–syyskuu 2025

28 de out. de 2025, 07:00 AM
GlobeNewswire Inc.

Orion-konsernin puolivuosikatsaus tammi–kesäkuu 2025

18 de jul. de 2025, 06:00 AM
GlobeNewswire Inc.

Sisäpiiritieto: Orion parantaa näkymäarviota vuodelle 2025

09 de jul. de 2025, 07:00 AM
GlobeNewswire Inc.

Orion ja Glykos laajentavat tutkimusyhteistyö- ja lisenssisopimustaan seuraavan sukupolven vasta-ainekonjugaattien kehittämiseksi

17 de jun. de 2025, 03:00 AM
GlobeNewswire Inc.

Orion and Glykos announce the extension of their research collaboration and licensing agreement for the development of next-generation ADCs

17 de jun. de 2025, 03:00 AM
GlobeNewswire Inc.

Orionin yhteistyökumppani MSD laajentaa opevesostaatin kliinistä kehitysohjelmaa naisten syöpiin

21 de mai. de 2025, 01:30 AM
GlobeNewswire Inc.

Orion-konsernin osavuosikatsaus tammi–maaliskuu 2025

23 de abr. de 2025, 06:00 AM
GlobeNewswire Inc.

Lääketeollisuus luovutti hallitukselle arvolupauksen: miljarditason investoinnit vuoteen 2030 mennessä

21 de mar. de 2025, 08:00 AM
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide

07 de jan. de 2025, 04:00 AM
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee Kiinassa kolmatta indikaatiota darolutamidille

07 de jan. de 2025, 04:00 AM
GlobeNewswire Inc.

Orion ja Abilita Therapeutics sopivat tutkimusyhteistyöstä ja lisenssisopimusoptiosta innovatiivisten vasta-ainehoitojen kehittämiseksi

18 de dez. de 2024, 12:00 PM
GlobeNewswire Inc.

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

18 de dez. de 2024, 12:00 PM
GlobeNewswire Inc.

Sisäpiiritieto: Orion lopettaa ODM-111-kehitysohjelman perustuen molekyylin liian kapeaan terapeuttiseen ikkunaan

24 de out. de 2024, 13:50 PM
GlobeNewswire Inc.

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

24 de out. de 2024, 13:50 PM
GlobeNewswire Inc.

Orionin yhteistyökumppani Bayer hakee EU:ssa kolmatta indikaatiota darolutamidille

14 de out. de 2024, 05:00 AM
GlobeNewswire Inc.

Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU

14 de out. de 2024, 05:00 AM
GlobeNewswire Inc.

Darolutamidi yhdessä ADT-hoidon kanssa pienensi merkitsevästi (46 prosentilla) syövän etenemisen tai kuoleman riskiä verrattuna lumelääkkeen ja ADT:n yhdistelmään levinnyttä hormonisensitiivistä eturauhassyöpää sairastavilla potilailla

16 de set. de 2024, 05:30 AM
Valor de mercado
404.87M
Valor da empresa
1.37B
P/L
P/VP
1.07
P/Receita
0.23
VE / EBITDA
6.46
VE / Receita
0.76
LPA
-1.58
Dividend yield
1.16%
Preço/FCF
11.53
P/Fluxo de caixa
1.99
Fluxo de caixa livre
35.1M
Retorno sobre patrimônio
-23.48%
Retorno sobre ativos
-4.61%
Dívida / Patrimônio
2.67
Índice de liquidez corrente
1
Índice de liquidez seca
0.62
Caixa
0.08
Volume médio
460.53K
Preço de referência fundamental
7.18

Demonstração de resultados

Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Receita 459.5M 411.7M 450.9M 466.4M 477.7M
Lucro bruto 79.2M 77.7M 85.6M 98.4M 98.1M
Lucro operacional 11.4M 13.5M -52.3M 32.1M 31.2M
EBITDA operacional 44.1M 41.3M 62.2M 64.1M 62.7M
Lucro líquido -9.9M -21.1M -67.1M 9M 9.1M
LPA básico -0.18 -0.37 -1.2 0.16 0.16
LPA diluído -0.18 -0.37 -1.2 0.16 0.16

Balanço patrimonial

Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Ativos totais 1.93B 1.91B 1.96B 2.02B 1.97B
Passivos totais 1.55B 1.52B 1.56B 1.56B 1.5B
Patrimônio líquido total 379.5M 384.6M 401.8M 466.5M 466.1M
Caixa e equivalentes 50.5M 60.7M 51.3M 42.6M 37.5M
Ativos circulantes 661.5M 643.8M 683.5M 682.5M 688.6M
Passivos circulantes 659.7M 626.4M 635.3M 620.8M 601.9M

Fluxo de caixa

Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Fluxo de caixa operacional -12.4M 92.9M 68.8M 53.7M 400K
Fluxo de caixa de investimento -36.1M -48.7M -40.9M -42.2M -29.2M
Fluxo de caixa de financiamento 39.6M -35.7M -19.5M -7.8M 21.8M
Variação no caixa -8.9M 8.5M 8.4M 3.7M -7M
Tipo Arquivamento Data URL
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index 10-Q — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
form 4 Form 4 — Niewiem Sandra Ver arquivamento
form 4 Form 4 — Painter Corning F. Ver arquivamento
form 4 Form 4 — Puckett Jonathan A. Ver arquivamento
form 4 Form 4 — Quinones Carlos Ver arquivamento
form 4 Form 4 — Riveros Pedro Ver arquivamento
edgar index ARS — Orion S.A. Ver arquivamento
edgar index DEF 14A — Orion S.A. Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index PRE 14A — Orion S.A. Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index SCHEDULE 13G — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
form 4 Form 4 — Niewiem Sandra Ver arquivamento
form 4 Form 4 — Niewiem Sandra Ver arquivamento
form 4 Form 4 — Niewiem Sandra Ver arquivamento
form 4 Form 4 — Painter Corning F. Ver arquivamento
form 4 Form 4 — Painter Corning F. Ver arquivamento
form 4 Form 4 — Painter Corning F. Ver arquivamento
form 4 Form 4 — Quinones Carlos Ver arquivamento
form 4 Form 4 — Quinones Carlos Ver arquivamento
form 4 Form 4 — Quinones Carlos Ver arquivamento
form 4 Form 4 — Riveros Pedro Ver arquivamento
form 4 Form 4 — Riveros Pedro Ver arquivamento
form 4 Form 4 — Riveros Pedro Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index 10-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
ten k section 10-K — business Ver arquivamento
ten k section 10-K — mda Ver arquivamento
ten k section 10-K — risk_factors Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
form 4 Form 4 — Puckett Jonathan A. Ver arquivamento
edgar index 3 — Orion S.A. Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index 10-Q — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
eight k text 8-K — 8-K Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index 10-Q — Orion S.A. Ver arquivamento
edgar index SCHEDULE 13G/A — Orion S.A. Ver arquivamento
edgar index 8-K — Orion S.A. Ver arquivamento
edgar index SCHEDULE 13G/A — Orion S.A. Ver arquivamento
edgar index 3 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
edgar index 4 — Orion S.A. Ver arquivamento
form 4 Form 4 — GALVIN KERRY A Ver arquivamento